RecruitingInterventional · Phase 1/2NCT03556228 ↗A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
Active, not recruitingInterventional · Phase 2NCT03600701 ↗A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerAshish SaxenaPIInterventionDrug: Atezolizumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Cobimetinib · Procedure: Computed Tomography · Procedure: Magnetic Resonance ImagingDatesNov 2018 – Jul 2025· Results postedSponsorNational Cancer InstituteMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 3NCT03833154 ↗A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR MutationSilvia Chiara FormentiPIInterventionDrug: Durvalumab · Other: Placebo · Drug: (Osimertinib cohort, single-arm, open-label separate cohort)DatesMar 2019 – Oct 2028 (est.)SponsorAstraZeneca, PLCCarcinoma, Non-Small-Cell Lung
Active, not recruitingInterventional · Phase 3NCT04214262 ↗A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCHani Lamie AshamallaPIInterventionDrug: Atezolizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation TherapyDatesAug 2020 – Aug 2024· Results postedSponsorSWOG Cancer Research NetworkLung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8
Active, not recruitingInterventional · Phase 2NCT04533451 ↗Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)Ashish SaxenaPIInterventionDrug: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Other: Comprehensive Geriatric Assessment · Other: Questionnaire Administration · Other: Quality-of-Life AssessmentDatesNov 2020 – Oct 2023· Results postedSponsorAlliance for Clinical Trials in OncologyMetastatic Lung AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Adenocarcinoma+2 more
Active, not recruitingInterventional · Phase 1NCT04794699 ↗An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid TumorsBarbara MaPIInterventionDrug: IDE397 · Drug: Sacituzumab govitecanDatesApr 2021 – Jan 2027 (est.)SponsorIDEAYA BiosciencesSolid Tumor
RecruitingInterventional · Phase 1/2NCT05361174 ↗A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerBarbara MaPIInterventionBiological: IOV-4001DatesJul 2022 – Sep 2027 (est.)SponsorIovance Biotherapeutics, IncUnresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung Cancer+1 more
Active, not recruitingInterventional · Phase 3NCT06500455 ↗Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain MetastasesHani Lamie AshamallaPIInterventionProcedure: Computed Tomography · Radiation: Fractionated Stereotactic Radiation Therapy · Procedure: Magnetic Resonance Imaging · Radiation: Stereotactic RadiosurgeryDatesDec 2024 – Jun 2028 (est.)SponsorNRG OncologyAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Digestive System Carcinoma+7 more
RecruitingInterventional · Phase 2NCT06623656 ↗Multicenter Randomized Phase II Trial of Neoadjuvant Radioimmunotherapy Versus Chemoimmunotherapy in Patients With Clinical Stages IB-III (N2) Non-small Cell Lung CancerNasser K AltorkiPIInterventionDrug: Cemiplimab · Drug: Platinum based chemotherapy · Radiation: Stereotactic body radiation therapyDatesFeb 2025 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityCarcinoma, Non-Small-Cell Lung
RecruitingInterventional · Phase 3NCT06712355 ↗A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung CancerAshish SaxenaPIInterventionDrug: Pumitamig · Drug: Atezolizumab · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)DatesFeb 2025 – Apr 2029 (est.)SponsorBioNTech SEExtensive-stage Small-cell Lung Cancer
RecruitingInterventional · Phase 2/3NCT07100080 ↗IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor TherapyAshish SaxenaPIInterventionDrug: Iza-bren · Drug: Carboplatin · Drug: Cisplatin · Drug: PemetrexedDatesNov 2025 – Dec 2028 (est.)SponsorBristol-Myers Squibb CompanyNon-Small Cell Lung Cancer
CompletedInterventional · Phase 2NCT03915951 ↗A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerAshish SaxenaPIInterventionDrug: encorafenib · Drug: binimetinibDatesJun 2019 – Sep 2022· Results postedSponsorArray BioPharma Inc.Non-small Cell Lung Cancer
CompletedInterventional · Not applicableNCT05890872 ↗A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced CancerBradley B PuaPIInterventionDevice: Aliya Pulsed Electric Fields (PEF)DatesSep 2023 – Aug 2025SponsorGalvanize Therapeutics, Inc.Lung Neoplasm Malignant